Dr. Doris Fuertinger discusses the future impact of novel therapeutic interventions on populations with kidney disease.

Dr. Hanjie Zhang discusses the benefits and risks of Generative AI in healthcare.

Dr. Giovanni Strippoli discusses how the CONVINCE study results will contribute to reaching a higher level of certainty regarding the comparative efficacy of hemodiafiltration versus HD in people with end-stage kidney disease.

Michelle Carver, Chief Nursing Officer and Senior Vice President of Nursing and Clinical Services at Fresenius Kidney Care, discusses the benefits and challenges of patients dialyzing at home.

Manuela Stauss-Grabo, PhD, leads the Global Biomedical Evidence Generation Team within Fresenius Medical Care’s Global Medical Office.

Krister Cromm, Fresenius Medical Care’s Director Person-Centered Outcomes Research, discuss the company’s evolution from disease-centered to person-centered integrated trial design.

Luca Neri, senior director of clinical advanced analytics at Fresenius Medical Care, discusses Anemia Management with AI and computational modeling.

Prof. Peter Blankestijn discusses the results of the multicenter CONVINCE Study including how the use of hemodiafiltration impacts patient morbidity and all-cause mortality as well as patient-reported outcomes.

Anjana Harve, Fresenius Medical Care’s Chief Information Office, talks about cybersecurity and the use of health information systems to improve the quality of care for patients.

Brigitte Schiller, Fresenius Medical Care’s senior vice president for home therapies, discusses the ecosystem and opportunities for patients to do dialysis in their own home.

David Rhew, Microsoft’s Chief Medical Officer and Vice President of Healthcare, discusses ChatGPT’s uses in healthcare.

Dr. Isaac “Zak” Kohane, Chair of the Department of Biomedical Informatics at Harvard Medical School discusses the adoption of artificial intelligence and machine learning in healthcare.